Rocket Pharmaceuticals (RCKT) Depreciation & Amortization (CF) (2015 - 2026)

Rocket Pharmaceuticals (RCKT) has 12 years of Depreciation & Amortization (CF) data on file, last reported at $1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 34.39% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $8.0 million (up 0.9% YoY), and the FY2025 full-year result was $8.9 million, up 22.85% from the prior year.
• Depreciation & Amortization (CF) declined to $1.6 million in Q1 2026, from $1.7 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.7 million in Q3 2025 to a low of $800000.0 in Q1 2022.
• A 5-year average of $1.6 million and a median of $1.7 million in 2025 frame the typical range for Depreciation & Amortization (CF).
• Across the five-year window, Depreciation & Amortization (CF) surged 53.69% in 2024 and tumbled 34.39% in 2026, its largest moves.
• Tracing RCKT's Depreciation & Amortization (CF) over 5 years: stood at $1.0 million in 2022, then surged by 39.6% to $1.4 million in 2023, then jumped by 30.52% to $1.8 million in 2024, then retreated by 7.9% to $1.7 million in 2025, then retreated by 4.17% to $1.6 million in 2026.
• Business Quant data shows RCKT's Depreciation & Amortization (CF) at $1.6 million in Q1 2026, $1.7 million in Q4 2025, and $2.7 million in Q3 2025.